To be eligible to seek access to givosiran through the early access program (EAP), participants must meet certain requirements, including, but not limited to:
Have not previously participated in, or are currently enrolled in, an ongoing interventional givosiran clinical trial
Have no known serious comorbidities, or any of the following laboratory parameter assessments at screening (including elevated liver enzymes), and must deemed to be fit for the program by treating physician, specifically:
If you are a patient interested in participating, please speak with your physician about the potential benefits and risks of taking part in the program.
The givosiran early access program is currently open in select countries in North America, Europe, and Asia. In the U.S., additional information can be found by visiting ClinicalTrials.gov/NCT04056481.
Only a licensed physician can request givosiran. If you are a patient who is interested in seeking access to givosiran through the early access program, please speak to your physician. Alnylam can only respond to a physician requesting access to givosiran on behalf of a patient in his/her care.
If you are a physician who is seeking to obtain access to givosiran for a patient in your care, please contact firstname.lastname@example.org.
If you are a physician or patient and have a medical question, please contact email@example.com.